TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21301952
Drug: Protocol for
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol for an Office‐based Nurse‐administered Intervention (PONI) administered on-site by trained nurses over the course of 3-6 months.
Study: 19237249
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy (group 3)
Study: 19237249
Drug: No opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No opioid therapy (group 2)
Study: 19237249
Drug: No pain
Normalized name: Biochemistry Heel No Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pain or opioid therapy (group 1)
Study: 17249848
Drug: Garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 600 mg as intact tablets
Study: 17249848
Drug: Garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 600 mg as crushed tablets via NG tube
Study: 17249848
Drug: Garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 600 mg as crushed tablets via NG tube with concomitant enteral feeding (Osmolite; 600 mL at 100 mL/h)
Study: 15236891
Drug: 24 h
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 h intravenous hydration
Study: 15236891
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous hydration (Control)
Study: 11597795
Drug: Cumulative duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative duration of combined therapy
Study: 9145729
Drug: Amoxicillin/clavulanate (875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (875/125 mg) every 12 hours
Study: 9145729
Drug: Amoxicillin/clavulanate (500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500/125 mg) every 8 hours
Study: 11557915
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 5 mg
Study: 3034316
Drug: enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enalapril maleate 10 mg orally
Study: 3034316
Drug: enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enalapril maleate 5 mg intravenously
Study: 3032562
Drug: enalaprilat 5
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enalaprilat 5 mg intravenously
Study: 3034316
Drug: oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of 10 mg enalapril maleate
Study: 26486702
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) influenza vaccine (15 µg)
Study: 26486702
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) influenza vaccine (15 µg)
Study: 25418440
Drug: Delayed primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed primary excision (DPE) with adjusted radiation therapy (RT) dose
Study: 25418440
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) dose of 36 Gy, 41.4 Gy, or 50.4 Gy based on DPE results
Study: 25418440
Drug: IRS-IV standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-IV standard treatment without DPE
Study: 15684258
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg.kg(‐1)
Study: 15684258
Drug: Lidocaine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.0 mg.kg(‐1)
Study: 15684258
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg(‐1)
Study: 11850268
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) - 2 mg/kg body weight
Study: 11850268
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (AMB-DOC) - 0.6 mg/kg body weight
Study: 1533259
Drug: Enalapril (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20-40 mg/day)
Study: 8557971
Drug: Nifedipine-GITS (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-GITS (30-60 mg/day)
Study: 8557971
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day for 2 weeks)
Study: 8557971
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg/day for 1 week)
Study: 1956698
Drug: Hybrid synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid synthetic polypeptide vaccine containing epitopes from four proteins of Plasmodium falciparum
Study: 6452794
Drug: Desipramine 75
Normalized name: desipramine 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 75 mg b.i.d.
Study: 6452794
Drug: Zimelidine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 100 mg b.i.d.
Study: 6215831
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Zimelidine and Desipramine)
Study: 26938214
Drug: Oral flucloxacillin
Normalized name: cloxacillin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flucloxacillin
Study: 26938214
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and topical placebos
Study: 16575724
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg/day) for 3 weeks
Study: 8657524
Drug: Breakfast with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast with 25% of daily phenylalanine allowance and lunch with 30%
Study: 8657524
Drug: Breakfast with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast with 50% of daily phenylalanine allowance and lunch with 10%
Study: 8657524
Drug: Breakfast with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast with 75% of daily phenylalanine allowance and lunch with 10%
Study: 1632391
Drug: Lovastatin, 40
Normalized name: Lovastatin, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin, 40 mg twice daily for 7 to 10 days before PTCA and continued for 6 months.
Study: 6837492
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg zinc added to vitamin and mineral supplements)
Study: 31375452
Drug: Nontargeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontargeted therapy
Study: 23417236
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 4 mL hylastan
Study: 23417236
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 4 mL hylastan
Study: 23417236
Drug: Steroid (IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (IA methylprednisolone acetate 40 mg)
Study: 23417236
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (2 × 4 mL hylastan, 1 × 4 mL hylastan, steroid)
Study: 22331761
Drug: Test: 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test: 0.2 mg misoprostol tablet
Study: 22331761
Drug: Reference: branded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference: branded misoprostol tablet
Study: 20655543
Drug: High-DHA algal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-DHA algal oil (∼200 mg/d of DHA)
Study: 2406859
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (300 mg every 30 minutes, total of 2.4 g in eight doses)
Study: 31513088
Drug: Bushen Tiaogan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Tiaogan formula (BSTG) plus traditional Chinese medicine-based psychotherapy (TBP)
Study: 31513088
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus traditional Chinese medicine-based psychotherapy (TBP)
Study: 28762354
Drug: Enamel microabrasion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel microabrasion (EM) followed by in‐office bleaching with 44% carbamide peroxide gel
Study: 23463625
Drug: Dose-modified capecitabine/irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab
Study: 8924193
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg citalopram infusion
Study: 3891362
Drug: Dihydroxybusulfan (B)
Normalized name: DIHYDROXYBUSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Dihydroxybusulfan (B) 600 mg/m2 p.o. for 4-6 weeks q 12 weeks
Study: 3891362
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (C) 150 mg/m2 p.o. for 7 days q 4 weeks
Study: 3891362
Drug: CAF (Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (Cyclophosphamide 400 mg/m2 i.v., doxorubicin 30 mg/m2, 5-fluorouracil 400 mg/m2 i.v., days 1 and 8 q 4 weeks)
Study: 31584944
Drug: Wirelessly observed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wirelessly observed therapy (WOT)
Study: 20551194
Drug: RCTs that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCTs that mentioned adverse drug reactions (ADRs)
Study: 20551194
Drug: RCTs that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCTs that tabulated adverse drug reactions
Study: 9566100
Drug: H15 (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: H15 (3600 mg daily)
Study: 7827399
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 microgram twice daily
Study: 7827399
Drug: Calcitriol 0.5
Normalized name: CALCITRIOL 0.5MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.5 to 1.0 micrograms/day plus calcium 1000 mg/day
Study: 7827399
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium 1000 mg/day
Study: 3137320
Drug: Low-volume enteral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume enteral feeds (12 ml/kg/day) in addition to parenteral alimentation for 10 days starting on day 8 of life
Study: 3137320
Drug: Parenteral alimentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral alimentation alone until day 18 of life
Study: 18307077
Drug: Advance provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advance provision of emergency contraceptive pills (ECP), condoms, and an information leaflet
Study: 17139825
Drug: Surfactant inhalations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant inhalations (700 mg cumulative dose over 8 weeks) during chemotherapy
Study: 20141732
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (control group)
Study: 12540551
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular vaccine
Study: 12540551
Drug: Intranasal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunization with CRM197 without chitosan
Study: 12540551
Drug: Unilateral intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral intranasal immunization
Study: 8731520
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg THA (tacrine)
Study: 8731520
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg THA (tacrine)
Study: 29706227
Drug: DMPA‐SC self‐injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA‐SC self‐injection
Study: 28514347
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment using ABO anthropometric system with indirect bonding
Study: 28514347
Drug: Conventional orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional orthodontic treatment protocol
Study: 23621161
Drug: high-dose statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose statins
Study: 20889053
Drug: Light-force chincup
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-force chincup (125-250 g)
Study: 15128463
Drug: Decision aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aid for antithrombotic therapy
Study: 11740232
Drug: IGF-1 treatment
Normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IGF-1 treatment
Study: 3321873
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amniotomy and oxytocin
Study: 2461906
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (HES) solution
Study: 10566563
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg once daily for 10 days)
Study: 14750614
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (250 mg twice daily for 10 days)
Study: 1879394
Drug: d-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (30 mg)
Study: 8912230
Drug: paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: paroxetine (20 mg)
Study: 3782648
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sublingual nifedipine
Study: 1841020
Drug: Maintenance nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance nifedipine therapy
Study: 6356628
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pirlindol
Study: 6356628
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pirlindol
Study: 6356628
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg pirlindol
Study: 6356628
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg imipramine
Study: 6356628
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tranylcypromine
Study: 6337608
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nomifensine
Study: 31050161
Drug: liraglutide-metformin
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide-metformin
Study: 31050161
Drug: placebo-metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-metformin
Study: 23538170
Drug: MABA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABA 400 μg once daily
Study: 23538170
Drug: MABA 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABA 1200 μg once daily
Study: 23538170
Drug: TIO +
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO + SAL (tiotropium 18 μg once daily plus salmeterol 50 μg twice daily)
Study: 19551272
Drug: 2 alternate
Normalized name: ALTERNARIA ALTERNATA
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 alternate daily preprandial measurements
Study: 19551272
Drug: 2 alternate
Normalized name: ALTERNARIA ALTERNATA
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 alternate daily pre‐ and postprandial measurements
Study: 9094151
Drug: Loxiglumide (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (2.4 g/day)
Study: 8249952
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (0.3 to 0.4 mg/kg)
Study: 30054920
Drug: Liraglutide 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.9 mg/d
Study: 30054920
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg/d
Study: 25223724
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg twice daily for 52 weeks (group A)
Study: 25223724
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg twice daily for 4 weeks and then 150 mg once daily (group B)
Study: 20200257
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of 80% CLA (50:50 cis-9,trans-11 and trans-10,cis-12 isomers)
Study: 20200257
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of 80% CLA
Study: 18519483
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 32 mg of docosahexaenoic acid and 31 mg of arachidonic acid per 100 mL of human milk
Study: 11206237
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg
Study: 18426147
Drug: Loratadine, 10
Normalized name: Loratadine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine, 10 mg
Study: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 20% of control
Study: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 40% of control (Group II)
Study: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 60% of control (Group III)
Study: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 80% of control (Group IV)
Study: 31872906
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin)
Study: 31872906
Drug: Conventional statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional statin therapy
Study: 27804174
Drug: Once-daily treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily treatment for asthma and COPD
Study: 20726255
Drug: Control vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccines
Study: 17931064
Drug: Relaxation response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation response (RR) tapes and soft music during acupuncture treatment; RR tapes listened to at home daily
Study: 17931064
Drug: Soft music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft music during acupuncture treatment (control group)
Study: 17931064
Drug: Relaxation response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation response (RR) tapes and soft music during acupuncture treatment
Study: 16087945
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U once weekly for 12 months
Study: 12390569
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered amoxicillin at 500 mg, 3 times daily for 14 days
Study: 12390569
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered metronidazole at 250 mg, 3 times daily for 14 days
Study: 12390569
Drug: SRP only
Normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP only or SRP followed by 14 days of orally administered doxycycline at 4 micro g/mL
Study: 2649130
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with triiodothyronine)
Study: 2649130
Drug: Sequential single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single agent therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with vincristine)
Study: 2649130
Drug: Sequential single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single agent therapy
Study: 7391628
Drug: A-Group: 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-Group: 900 mg of calcium, 50 mg of sodium fluoride, 50,000 units of vitamin D twice weekly
Study: 7391628
Drug: B-Group: 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-Group: 900 mg of calcium, 50 mg of sodium fluoride
Study: 7391628
Drug: C-Group: 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-Group: 50 mg of sodium fluoride
Study: 7391628
Drug: D-Group: 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Group: 900 mg of calcium, 50 mg of sodium fluoride, 2 mg of estriol
Study: 7391628
Drug: E-Group: 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-Group: 2 mg of estriol
Study: 7391628
Drug: F-Group: 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-Group: 900 mg of calcium
Study: 7391628
Drug: G-Group: 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Group: 900 mg of calcium, 2 mg of estriol
Study: 26721134
Drug: Acupuncture-moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-moxibustion treatment (14 sessions, based on Zusanli, Yinlingquan, Zhongwan, Danzhong, Neiguan, Taichong, Ganshu, Geshu, Danshu)
Study: 26721134
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Chinese herbs, one dose a day for 4 weeks)
Study: 22405557
Drug: One-dose-adjuvanted primary
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose-adjuvanted primary administration followed by a single-adjuvanted booster dose containing a heterologous vaccine strain